前往主要內容區間
掛號頁面

血液暨腫瘤科

  • 林建鴻醫師相片

    林建鴻

    主任

    血液暨腫瘤科 :
    台北門診掛號  淡水門診掛號

    林建鴻醫師本頁二維碼

  • 現職

      馬偕紀念醫院 血液腫瘤科主任
      馬偕醫學院醫學系 兼任助理教授
      馬偕紀念醫院 血液腫瘤科 資深主治醫師

    主要學歷

      臺灣大學 腫瘤醫學研究所博士
      臺灣大學 醫學士

    主要經歷

      美國 Mayo Clinic 血液科研究員
      腫瘤內科專科醫師
      血液病專科醫師
      內科專科醫師

    其他相關

      <學會會員>
      台灣內科醫學會
      中華民國癌症醫學會
      中華民國血液病學會
      台灣安寧緩和醫學會
      <證書>
      醫師證書
      內科專科醫師證書
      中華民國血液病專科醫師證書
      中華民國腫瘤內科專科醫師證書

主治項目或專長

血液病: 貧血、血球異常、紫斑症、紅血球增多症、血小板增多症、嗜酸性白血球增多症、骨髓纖維化症、白血病、淋巴瘤、多發性骨髓瘤、肥大細胞增多症。

固態腫瘤: 軟組織肉瘤、胃腸道癌症、泌尿道癌症、轉移性癌症及其它各類惡性腫瘤 。


論文研究

  1. Chang YC, Chiang YH, Hsu K, Chuang CK, Kao CW, Chang YF, Chang MC, Lim KH*, Cheng HI, Hsu YN, Chen CG. Activated naïve γδ T cells accelerate deep molecular response to BCR-ABL inhibitors in patients with chronic myeloid leukemia. Blood Cancer Journal 2021 Nov 16; 11(11): 182.

  2. Lim KH*, Matsuura S, Xu B. Editorial: novel treatment strategies for myeloproliferative neoplasms. Front Oncol. 2021 Sep 15.

  3. Lim KH*, Wu JN, Huang TY, Jhuang JY, Chang YC, Lin HC, Chiang YH, Su YW, Chen GS, Chang YF, Lim J. Clonal evolution and heterogeneity in advanced systemic mastocytosis revealed by single-cell DNA sequencing. Blood Adv. 2021 Mar 23; 5(6): 1733-36

  4. Lai YH, Audira G, Liang ST, Siregar P, Suryanto ME, Lin HC, Villalobos O, Villaflores OB, Hao E, Lim KH*, Hsiao CD. Duplicated dnmt3aa and dnmt3ab DNA methyltransferase genes play essential and non-overlapped functions on modulating behavioral control in zebrafish. Genes. 2020 Nov 7;11(11):1322.

  5. Cheng CC, Lin HC, Chiang YW, Chang J, Sie ZL, Yang BL, Lim KH*, Peng CL, Ho AS, Chang YF. Nicotine exhausts CD8+ T cells against tumor cells through increasing miR-629-5p to repress IL2RB-mediated granzyme B expression. Cancer Immunol Immunother. 2021 May 70(5): 1351-64.

  6. Lim KH*, Chen LC, Hsu K, Chang CC, Chang CY, Kao CW, Chang YF, Chang MC, Chen CG. BAFF-driven NLRP3 inflammasome activation in B cells. Cell Death & Disease 2020 Oct 1; 11(9): 820.

  7. Chang YF, Lim KH*, Chiang YW, Sie ZL, Chang J, Ho AS, Cheng CC. STAT3 induces G9a to exacerbate HER3 expression for the survival of epidermal growth factor receptor-tyrosine kinase inhibitors in lung cancers. BMC Cancer. 2019 Oct 16;19(1):959.

  8. Chang MC, Cheng HI, Hsu K, Hsu YN, Kao CW, Chang YF, Lim KH*, Chen CG. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia. Front Immunol. 2019 Jan 17;9:3152.

  9. Cheng CC, Lin HC, Tsai KJ, Chiang YW, Lim KH*, Chen CG, Su YW, Peng CL, Ho AS, Huang L, Chang YC, Lin HC, Chang J, Chang YF. Epidermal growth factor induces STAT1 expression to exacerbate the IFNr-mediated PD-L1 axis in epidermal growth factor receptor-positive cancers. Mol Carcinog. 2018 Nov;57(11):1588-1598.

  10. Cheng CC, Liao PN, Ho AS, Lim KH*, Chang J, Su YW, Chen CG, Chiang YW, Yang BL, Lin HC, Chang YC, Chang CC, Chang YF. STAT3 exacerbates survival of cancer stem-like tumorspheres in EGFR-positive colorectal cancers: RNAseq analysis and therapeutic screening. J Biomed Sci. 2018 Aug 2;25(1):60.

  11. Chiang YH, Chang YC, Lin HC, Huang L, Cheng CC, Wang WT, Cheng HI, Su NW, Chen CG, Lin J, Chang YF, Chang MC, Hsieh RK, Chou WC, Lim KH*, Kuo YY. Germline variations at JAK2, TERT, HBS1L-MYB and MECOM and the risk of myeloproliferative neoplasms in Taiwanese population. Oncotarget. 2017 Jul 12.

  12. Lim KH*, Chen CG, Chang YC, Chiang YH, Kao CW, Wang WT, Chang CY, Huang L, Lin CS, Cheng CC, Cheng HI, Su NW, Lin J, Chang YF, Chang MC, Hsieh RK, Lin HC, Kuo YY. Increased B cell activation is present in JAK2V617F-mutated, CALR-mutated and triple-negative essential thrombocythemia. Oncotarget. 2017 May 16; 8(20):32476-32491.

  13. Chang YC, Lin HC, Chiang YH, Chen CG, Huang L, Wang WT, Cheng CC, Lin J, Chang YF, Chang MC, Hsieh RK, Chen SJ, Lim KH*, Kuo YY. Targeted next-generation sequencing identified novel mutations in triple-negative myeloproliferative neoplasms. Med Oncol. 2017 May; 34(5):83.

  14. Ken-Hong Lim*, Yu-Cheng Chang, Yi-Hao Chiang, Huan-Chau Lin, Chiao-Yi Chang, Ching-Sung Lin, Ling Huang, Wei-Ting Wang, Caleb Gon-Shen Chen, Wen-Chien Chou, and Yuan-Yeh Kuo. Expression of CALR mutants causes mpl-dependent thrombocytosis in zebrafish. Blood Cancer Journal. 2016, Oct; 6, e481.

  15. Lin HC, Hwang DY, Lim KH*. Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms. Med Oncol. 2016 Aug; 33(8):92.

  16. K-H Lim*, Y-C Chang, C Gon-Shen Chen, H-C Lin, W-T Wang, Y-H Chiang, H-I Cheng, N-W Su, J Lin, Y-F Chang, M-C Chang, R-K Hsieh, Y-Y Kuo and W-C Chou. Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer Journal. 2015, Mar; 5, e295.

  17. Lim KH*, Lin HC, Chen CG, Wang WT, Chang YC, Chiang YH, et al. Rapid and sensitive detection of CALR exon 9 mutations using high-resolution melting analysis. Clin Chim Acta 2015 ;440: 133-9.

  18. Liu CC, Wang SC, Kao CW, Hsieh RK, Chang MC, Chang YF, Lim KH*, Chen CG. B cells facilitate platelet production mediated by cytokines in patients with essential thrombocythaemia. Thromb Haemost. 2014 Sep; 112(3): 537-50.

  19. KH Lim*, HC Lin, C Gon-Shen Chen, YH Chiang, CD Hsiao, YY KuoCALR Mutations in Myeloproliferative Neoplasms. International Journal of Gerontology. 2014, Jun.

  20. Huan-Chau Lin, Caleb Gon-Shen Chen, Ming-Chih Chang, Wei-Ting Wang, Chen Wei Kao, An-Chi Lo, Nai-Wen Su, Yu-Cheng Chang, Yi-Hao Chiang, Kuei-Fang Chou, Po-Nien Liao, Guan-Jhe Cai, Hung-I. Cheng, Johnson Lin, Yi-Fang Chang, Ruey-Kuen Hsieh, Ken-Hong Lim*. Mutation and lineage analysis of DNMT3A in BCR-ABL1-negative chronic myeloproliferative neoplasms. International Journal of Gerontology. 2013, Sep; 7(3), 186-188.

  21. Huan-Chau Lin, Caleb Gon-Shen Chen, Ming-Chih Chang, Wei-Ting Wang, Chen Wei Kao, An-Chi Lo, Nai-Wen Su, Yu-Cheng Chang, Yi-Hao Chiang, Kuei-Fang Chou, Po-Nien Liao, Guan-Jhe Cai, Hung-I. Cheng, Johnson Lin, Yi-Fang Chang, Ruey-Kuen Hsieh, Ken-Hong Lim*. JAK2 V617F mutation in adult Taiwanese patients with essential thrombocythemia: More prevalent in old patient and correlated with higher hemoglobin level and higher leukocyte count. International Journal of Gerontology. 2013, Mar; 7(1), 40-44.

  22. Yi-Hao Chiang, Yi-Fang Chang, Ruey-Kuen Hsieh, Johnson Lin,Caleb Gonshen Chen, Ken-Hong Lim*, Huan-Chau Lin and Ming-Chih Chang. Upfront maintenance therapy with arsenic trioxide in acute promyelocytic leukemia provides no benefit for non-t(15;17) subtype . Asia–Pacific Journal of Clinical Oncology, 2012, Dec; 8(4):330-336.

  23. Ho-Lien Huang, Chun-Nan Yeh, Kang-Wei Chang, Jenn-Tzong Chen , Kun-Ju Lin, Li-Wu Chiang, Kee-Ching Jeng, Wei-Ting Wang, Ken-Hong Lim*, Caleb Gonshen Chen, Kun-I Lin, Ying-Cheng Huang, Wuu-Jyh Lin, Tzu-Chen Yen, Chung-Shan Yu. Synthesis and evaluation of [18F]Fluorobutyl ethacrynic amide: a potential PET tracer for studying glutathione transferase. Bioorganic & medicinal chemistry letters. 2012, Jun; 22(12): 3998-4003.

  24. Ken-Hong Lim*, Yuan-Hsin Chang. Interstitial lung disease and gefitinib. The New England journal of medicine. 2010, Oct. ,Animesh Pardanani, Ken-Hong Lim*, Terra L. Lasho, Christy M. Finke, Rebecca F. McClure, Chin-yang Li and Ayalew Tefferi. WHO sub-variants of indolent mastocytosis: clinical details and prognostic evaluation in 159 consecutive adults. Blood. 2010, Jan; 115(1):150-151.

  25. Ken-Hong Lim*, Animesh Pardanani, Joseph H. Butterfield, Chin-Yang Li and Ayalew Tefferi. Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. American Journal of Hematology. 2009, Dec; 84(12):790-794.

  26. Animesh Pardanani, Ken-Hong Lim*, Terra L. Lasho, Christy Finke, Rebecca F. McClure, Chin-Yang Li and Ayalew Tefferi. Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. Blood. 2009, Oct; 114:3769-3772.

  27. Ayalew Tefferi, Ken-Hong Lim*, Ross Levine. Mutation in TET2 in myeloid cancers. New england journal of medicine. 2009, Sep; 361:1117.

  28. Ayalew Tefferi, Ken-Hong Lim*, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM, Hanson CA, Pardanani A, Gilliland DG, Levine RL. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia. 2009, Jul; 23:1343-1345.

  29. Ken-Hong Lim*, Ayalew Tefferi, Terra L. Lasho, Christy Finke, Mrinal Patnaik, Joseph H. Butterfield, Rebecca F. McClure, Chin-Yang Li and Animesh Pardanani. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009, Jun; 113:5727-36.

  30. Tefferi A, Levine RL, Lim KH*, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia. 2009, May; 23:900-904.

  31. Lim KH*, Pardanani A, Tefferi A. KIT and mastocytosis. Acta Haematol. 2008; 119(4):194-8. Epub 2008 Jun 20. Review., Tefferi A, Pardanani A, Lim KH*, Abdel-Wahab O, Lasho TL, Patel J, Gangat N, Finke CM, Schwager S, Mullally A, Li CY, Hanson CA, Mesa R, Bernard O, Delhommeau F, Vainchenker W, Gilliland DG, Levine RL. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009, May; 23:905-911.

  32. Lim KH*, Huang MJ, Chen LT, Wang TE, Liu CL, Chang CS, Liu MC, Hsieh RK, Tzen CY. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Med Oncol. 2008; 25(2):207-13., Lim KH*, Chiou TY, Lin CJ, Hsieh RK. Rituximab in the treatment of primary bilateral adrenal lymphoma with adrenal crisis. Med Oncol. 2008; 25(1):107-9.

  33. Lin CJ, Hsieh RK, Lim KH*, Chen HH, Cheng YC, Wu CJ. Fatal spontaneous tumor lysis syndrome in a patient with metastatic, androgen-independent prostate cancer. South Med J. 2007 Sep; 100(9):916-7.

  34. Lin CJ, Lim KH*, Cheng YC, Chen HH, Wu CJ. Tumor lysis syndrome after treatment with gemcitabine for metastatic transitional cell carcinoma. Med Oncol. 2007; 24(4):455-7.

  35. Lim KH*, Huang MJ, Liu HC, Kuo HT, Tzen CY, Hsieh RK. Lack of prognostic value of EGFR mutations in primary resected non-small cell lung cancer. Med Oncol. 2007; 24(4):388-93.